BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $FDMT readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05248230-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:~CF readout (P2) · 4D Molecular Therapeutics $FDMT
DESCRIPTION:4D-710 in Adult Patients With Cystic Fibrosis\n\nPrimary comple
 tion date: 2027-06 (estimated) — month only\, shown on the 1st\nOriginal
 ly planned: 2024-08 (+34.0 months)\nPhase 2 · Rare · Cystic Fibrosis Lun
 g\nEnrollment: 30 · Sites: 20\n\nPrimary completion = last participant's 
 primary-endpoint data collected\; topline results usually follow weeks to 
 months later. Sponsor-reported\, often an estimate. Not investment advice.
 \n\nhttps://datacutoff.com/radar.html?nct=NCT05248230\nhttps://clinicaltri
 als.gov/study/NCT05248230
URL:https://datacutoff.com/radar.html?nct=NCT05248230
CATEGORIES:Rare,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06864988-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:~4D-150 IVT (3E10 vg/eye) readout (P3) · 4D Molecular Therapeutics
  $FDMT
DESCRIPTION:4D-150 in Patients With Macular Neovascularization Secondary to
  Age-Related Macular Degeneration\n\nPrimary completion date: 2027-06 (est
 imated) — month only\, shown on the 1st\nPhase 3 · Eye · Macular Neova
 scularization Secondary to Age-Related Macular…\nEnrollment: 480 · Site
 s: 94\n\nPrimary completion = last participant's primary-endpoint data col
 lected\; topline results usually follow weeks to months later. Sponsor-rep
 orted\, often an estimate. Not investment advice.\n\nhttps://datacutoff.co
 m/radar.html?nct=NCT06864988\nhttps://clinicaltrials.gov/study/NCT06864988
URL:https://datacutoff.com/radar.html?nct=NCT06864988
CATEGORIES:Eye,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07064759-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:~4FRONT-2 readout (P3) · 4D Molecular Therapeutics $FDMT
DESCRIPTION:Single Intravitreal (IVT) Injection of 4D-150 in Patients With 
 Macular Neovascularization Secondary to Age-Related Macular Degeneration\n
 \nPrimary completion date: 2027-11 (estimated) — month only\, shown on t
 he 1st\nOriginally planned: 2028-11 (-12.0 months)\nPhase 3 · Eye · Neov
 ascular Age-Related Macular Degeneration (nAMD)\nEnrollment: 480 · Sites:
  126\n\nPrimary completion = last participant's primary-endpoint data coll
 ected\; topline results usually follow weeks to months later. Sponsor-repo
 rted\, often an estimate. Not investment advice.\n\nhttps://datacutoff.com
 /radar.html?nct=NCT07064759\nhttps://clinicaltrials.gov/study/NCT07064759
URL:https://datacutoff.com/radar.html?nct=NCT07064759
CATEGORIES:Eye,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
